Greetings, everyone, and welcome to Friday. Andrew Joseph here filling in for Pharmalot himself, and doing our best to channel the man, the myth, the legend. As we turn our sights to the weekend, we dream of prescription-free naps, simmering pots of soup, and relaxing quaffs of both the stimulatory and adult varieties. But for now, there’s news to catch up on. Many of you are kicking back after basking in the annual biopharma bacchanalia in San Francisco, but don’t forget those of us still burning the oil on this final day of the week. (Programming note: Pharmalittle will be off for the Monday holiday and will return Tuesday.)

A plan in India to fight high drug prices is facing blowback from the country’s pharmaceutical industry, Bloomberg informs us. That’s left the Draft Pharmaceutical Policy, which was announced last summer, in limbo. The country’s Department of Pharmaceuticals was supposed to revise the proposal, but now it’s no longer expected to in the current government term.

Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!


What is it?

STAT Plus is a premium subscription that delivers daily market-moving biopharma coverage and in-depth science reporting from a team with decades of industry experience.

What's included?

  • Authoritative biopharma coverage and analysis, interviews with industry pioneers, policy analysis, and first looks at cutting edge laboratories and early stage research
  • Subscriber-only networking events and panel discussions across the country
  • Monthly subscriber-only live chats with our reporters and experts in the field
  • Discounted tickets to industry events and early-bird access to industry reports

Leave a Comment

Please enter your name.
Please enter a comment.

Sign up for our Daily Recap newsletter

A roundup of STAT’s top stories of the day in science and medicine

Privacy Policy